infection at least addressing the utility of intrapleural fibrinolytics. This study is likely to suffer with very substantial selection bias, and with no comparison group • The authors should clearly explain how the number of doses was chosen, how interventions were chosen and how clinical outcomes were defined and chosen.
• The authors in two places make the clear point that treatment "success" was defined radiologically and clinically -and yet supply no data on the clinical parameters for success.
• In addition, the radiological parameters ("near complete resolution") require much better definition.
• The definition of "complicated effusion" is not standard, as this usually refers to definition of the pleural pH as per Heffner's metaanalysis. Another term should be used here.
• In the Methods section -"all patients that presented with fever, cough…. Were also treated with antibiotics" -does this mean some patients in the pleural infection group were not treated with antibiotics? How many of those with confirmed pleural infection were not treated with antibiotics? Numbers are needed here please.
• This is a retrospective case series of the use of fibrinolysis, and therefore the patient population are highly selected (by clinicians choosing to use fibrinolysis). This is carefully explained in the methods section, but requires further discussion as a major limitation of the study, and certainly limits any possible conclusions.
• The number of culture positive cases in infected pleural disease (78%) is very high compared to the published literature -why might this be? It again argues for a highly selected (and therefore likely unrepresentative) sample of patients • Success rate of treatment -"it was clear that" -instead of statements such as this, the authors should provide statistical comparison via the chi squared test of the treatment proportion success please comparing these 3 groups (and no statistical comparison is made).
• The population presented here is heterogenous population -is it therefore valid to combine the data?
• Please remove text such as "even higher" (page 12 line 37) which are not useful • Concerning bleeding complications, the authors should carefully assess the placebo controlled randomised trial literature in pleural infection -there are clearly documented cases of patients with intrapleural bleeds in the placebo arm of trials assessing fibrinolytic therapy. Is it therefore valid that bleeding complications are "the most feared complication" of fibrinolytic therapy , or are they simply a feature of complex pleural disease which is drained? • Figure 1 is labelled "study design" -but this study was not designed (as a retrospective study only). It is made to look like a consort diagram, and in my view should be removed.
• Given the limitations highlighted above, the conclusions made from the data should be carefully considered -I agree with the novel and interesting finding of the predictive value of pleural thickening on CT, but further conclusions should be carefully worded.
VERSION 1 -AUTHOR RESPONSE
Reviewer One: Laura Bonanno, MD Medical Oncologist.
Q1. The CT scan measurement of the reduction in effusion volume would have further improved the quality of the data.
A: Yes we agree this data would have been very interesting to obtain, unfortunately due to resource constraints; no volumetry was done systematically for our patients. single "clinical group" (infection, hemothorax, malignant) and the potential association with the time from the diagnosis to the treatment.
Q2. It could be interesting to include the indication of the percentage of pleural thickening in each
A: Pleural thickening was noted in 119/227 (51.5%) patients overall. This included 84/163 (51.5%) of the Empyema/CPE patients, 10/23(43.5%) of the hemothorax patients and 20/32 (62.5%) of the malignant effusion cases. As well as 5/9 (55.5%) of the undiagnosed effusions. There were thus no significant differences between groups. This has been added to the text (see page 12, second paragraph line 6). While it was very difficult to ascertain the exact timeline for many of the cases, in particular with the malignant effusion group, we do believe that it is a sign of chronicity of the overall effusion process.
Q3. The introduction of a table summarizing the different results in the different clinical groups could improve the clarity of the article (the information is already in the text)
A: A It is noteworthy that many of these factors were excluded in the protocol of the largest RCT published on this question. Indeed, while an RCT is methologically rigorous, it requires a fixed protocol to be evaluated, typically and optimally in multiple centers; thus, a flawed protocol will lead to negative results regardless of study design. Indeed, numerous centers have abandoned the use of intrapleural fibrinolytics due to a large multi-center negative RCT published in a prestigious journal, and thus, we believe that prospective case series are essential to further refine the protocol of how intrapleural fibrinolytics are administered, and importantly, how patients with complicated pleural effusions are managed.
Q2: The authors should clearly explain how the number of doses was chosen, how interventions were chosen and how clinical outcomes were defined and chosen.
A: The number of doses was chosen after consultation with the clinical pharmacist.
As there was no standard t-PA dose recommended at the time, the approach was a practical one. The vials of t-PA available in our hospital come in 50mg (t-PA, Roche, 1350$ USD),-this was frozen and sent out in 16mg fractions daily for 3 days. Interventions were chosen by the treating physician at the time; clinical outcomes were defined and assessed by the treating team involved. This information has been added (see page 6, 2 nd paragraph line 7). We have also added a table that describes our current technique of application. (Table-7) Q3: The authors in two places make the clear point that treatment "success" was defined radiologically and clinically -and yet supply no data on the clinical parameters for success.
A: Clinical parameters of success are defined as resolution of symptoms of infection and pleural effusion (including dyspnea, fever, pleuritic pain and elevated WBC), and the patient did not require further intervention (other than pleural drainage). The clinical assessment of success was performed in an ongoing fashion by the treating team at the time and reviewed by the authors. 5/227 (2.2%) patients did not have resolution of their symptoms, these were exclusively malignant effusions. This has been added to the Text (see page 7 last paragraph line 3, and page 12, first paragraph, line5).
Q4: In addition, the radiological parameters ("near complete resolution") require much better definition.
A: While fundamentally we agree with this point, resource limitations precluded the re-assessment and volumetry to be performed on all scans. While a clear definition is difficult, we relied on the radiological description of the chest radiologist.
Q5: The definition of "complicated effusion" is not standard, as this usually refers to definition of the pleural pH as per Heffner's meta-analysis. Another term should be used here.
A: The term complicated effusion relates here to the radiological character, i.e. loculated effusion and not "free" fluid and not to Heffner's meta-analysis.
Q6: In the Methods section -"all patients that presented with fever, cough…. Were also treated with antibiotics" -does this mean some patients in the pleural infection group were not treated with antibiotics? How many of those with confirmed pleural infection were not treated with antibiotics? Numbers are needed here please.
A: All patients with confirmed pleural infection were treated with antibiotics.
11/23 hemothorax patients received antibiotics as well as 30/32 of the malignant effusions. The text has been edited for clarification (see page 9, 3 rd paragraph, line 3).
Q7: This is a retrospective case series of the use of fibrinolysis, and therefore the patient population are highly selected (by clinicians choosing to use fibrinolysis). This is carefully explained in the methods section, but requires further discussion as a major limitation of the study, and certainly limits any possible conclusions.
A: Yes, this is a retrospective case series of the use of fibrinolytics. We do acknowledge that there are randomized controlled trials that provide evidence on the use of fibrinolytic therapy in infected pleural effusions/empyema.
We feel however that our manuscript demonstrates the application and utility of this therapy with image guided pleural drainage and intrapleural fibrinolysis, along with CT scan re-assessment, and additional pleural drainage if required in a large number of patients. Nonetheless, the reviewer is absolutely correct to point out the limitations of selection bias in a prospective series. To briefly address this, while we have not collected the data of patients at our institution with complicated pleural effusions that were treated with other forms of therapy, it is our experience that it is extremely rare at our institution to take a patient direct to surgery. Rather, we attempt a trial of pleural drainage and fibrinolysis, and in addition, we do not avoid draining large infected pleural collections. Thus, while we do not have the data, it is our best estimate that this patient population represents over 95% of all patients with complicated pleural effusions at our institution. While a case series is lacking in methodological rigor, we believe that our clinical and radiologic protocol provided superior results to those evaluated in large RCTs. Nonetheless, to truly evaluate the impact of this therapy vs. other forms of therapy (e.g. early surgery), an RCT would be required. This is further discussed in the last paragraph of the discussion (see page 16).
Q8: The number of culture positive cases in infected pleural disease (78%) is very high compared to the published literature -why might this be? It again argues for a highly selected (and therefore likely unrepresentative) sample of patients.
A: While it is correct that this was elevated, we believe it represents one of the guiding principles, namely rapid pleural drainage. The study took place in a tertiary care center with 24/7 thoracic surgery coverage, with resident physicians able to place pleural drains immediately. We do not feel this represents a selection bias; our direct catchment area has a population of 1.4 million with indirect referrals of a second population area of approx. 50,000. However the large proportion of culturepositive infected effusions highlights the severity of empyemas being treated. This is mentioned in the last paragraph of the discussion (see page 16 paragraph 2 line 6).
Q9: Success rate of treatment -"it was clear that" -instead of statements such as this, the authors should provide statistical comparison via the chi squared test of the treatment proportion success please comparing these 3 groups (and no statistical comparison is made).
A: Thank you; we have edited the text to include the Statistical comparison.
Chi-square test for success, empyema/CPE (p=.028), hemothorax (p= .08), Malignant effusion (p=.8) (see page 10, 2 nd paragraph, line 4)
Q10: The population presented here is heterogenous population -is it therefore valid to combine the data?
A: Our study is a retrospective analysis of the use of fibrinoyltic therapy in complicated pleural effusions that describes the approach and results in a heterogenous population as presenting to a tertiary care/referral center.
As our main interest was to look at factors related to failure and bleeding regardless of the cause of these effusions, it seemed appropriate to pool the data. A: That is a very insightful question. Is bleeding simply from fibrinolytic therapy? or is it from lung expansion that has torn a vascular adhesion in the pleural space for example? Bleeding may also come from pleural tube placement. As always, it is difficult to separate illness from treatment, which is frequently the case in surgery and critical illness. Nonetheless, our experience noted a temporal association between bleeding and fibrinolytic therapy, which suggested that use of fibrinolytic therapy was the principal cause of bleeding, but not always.
Q12: Figure 1 
GENERAL COMMENTS
There are several remaining issues: 1. In the reply to the reviewers comments, the authors have attempted a response to the point about the presence of placebo controlled trials on this subject. The argument that prospective case series add data above beyond placebo controlled trials is not unreasonable, however, the authors should in my view clearly state that placebo controlled trials thus far published (which had a comparison group, and therefore permit conclusions to be drawn about true efficacy) do not overall support the use of fibrinolytic therapy. The study described here suggests a "high" success ratebut there is no comparison group and therefore this needs to be stated clearly in the abstract and conclusions, i.e. that any suggestion of benefit from intrapleural fibrinolytic therapy from this data is uncertain and cannot be estimated. 2. The authors have clearly stated the definition of treatment success which improves the paper -however, I would like it to be stated whether the definition of treatment success was decided prior to assessing the data or post hoc? This should be clearly stated in the methods section of the manuscript
